Diabetic Nephropathy | Landscape & Forecast | Disease Landscape & Forecast

Publish date: August 2019

Login to access report

Diabetic nephropathy (DN), also referred as diabetic kidney disease, is a common complication of diabetes. Current standard of care fails to halt the frequent progression of DN to kidney disease and, ultimately, kidney failure—a condition associated with severe morbidity / mortality and high costs to patients, payers, and healthcare systems. As a result, key opinion leaders indicate that efficacious therapies for DN are a major unmet need, and they weigh in on the anticipated nephroprotective effects that endothelin receptor antagonists, mineralocorticoid receptor antagonists, and SGLT-2 inhibitor may offer. These therapies represent the first potentially disease-modifying therapies, should they prove efficacious and safe. The increasing prevalence of DN, exacerbated by the dynamics between clinicians seeking to prescribe new, premium-priced therapies and payers seeking to control costs among an already expensive population, will help shape the changing DN market over the next ten years.

Questions answered

  • Will the inclusion of cardiovascular endpoints in the clinical trials for select therapies be a competitive advantage once commercially available?
  • How do KOLs view the different mechanisms of action of the different therapies in early- and late-phase clinical development?
  • What are the greatest remaining unmet needs in DN? Which drugs in development will fulfill these unmet needs?
  • What market access and reimbursement challenges will the emerging therapies face in the G7? How will these challenges influence their uptake?

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • August 2019
      • June 2019
      • March 2019
    • Executive Summary
      • Key Findings
    • Market Outlook
      • Key Findings
        • Expert Insight
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Diabetic Nephropathy?
        • What Factors Are Constraining the Market for Diabetic Nephropathy?
      • Drug Class-Specific Trends
        • Sodium-Glucose Co-Transporter 2 Inhibitors
        • Antidiabetics
        • Mineralocorticoid Receptor Antagonists
        • Antihypertensives
    • Forecast
    • Etiology and Pathophysiology
      • Key Findings
        • Expert Insight
      • Pathophysiology
        • Pathophysiology
      • Natural History of Diabetic Nephropathy
        • Natural History
      • Risk Factors
        • Risk Factors
      • Key Pathways and Drug Targets
    • Epidemiology Overview
      • Key Findings
        • Expert Insight
      • Epidemiology Populations
        • Total Prevalent Cases of Diabetic Nephropathy
        • Diagnosed Prevalent Cases of Diabetic Nephropathy
        • Drug-Treated Cases of Diabetic Nephropathy
    • Current Treatment Overview
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Renin-Angiotensin-Aldosterone System Inhibitors
        • Other Antihypertensive Drug Classes
        • SGLT-2 Inhibitors for Type 2 Diabetes
        • Other Antidiabetics
      • Medical Practice
        • Overview
        • Drug Selection
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Diabetic Nephropathy
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Diabetic Nephropathy
        • Sodium-Glucose Co-Transporter 2 Inhibitors
        • Mineralocorticoid Receptor Antagonists
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Diabetic Nephropathy/Diabetic Kidney Disease
      • Key Discontinuations and Failures in Diabetic Nephropathy
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Diabetic Nephropathy Bibliography

Author(s): Dwaipayan Chatterjee, M.Pharm; Shreya Saxena, MBA

Dwaipayan Chatterjee is an Analyst in the Cardiovascular, Metabolism Renal and Hematology disease team at Decision Resources Group. He holds a degree with specialization in Pharmaceutical Chemistry from Birla Institute of Technology & Science, Pilani, Rajasthan, India. Prior joining DRG, he worked as an Equity Analyst for the Healthcare sector with Market Realist working on competitive intelligence and analysis of pharmaceutical financial data. He also worked as a market research analyst for Mordor Intelligence with experience of market sizing, forecasting, and analyzing market dynamics.

Shreya Saxena is a senior business insights analyst in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group. She obtained an degree with specializations in Marketing and HR, and a Bachelor's degree in Pharmacy from the GGSIPU University, Delhi, India. Prior to joining DRG, she has worked as a Business Analyst at the research firm Evalueserve. Her role involved in-depth commercial, and scientific secondary research, and competitive intelligence across multiple indications (such as atrial fibrillation, ACS, VTE, heart failure and women’s health), including pipeline analysis, clinical trials assessment, disease landscaping, product and company profiling, and financial assessment and benchmarking.